Hot line:010-83057670
EN-
312020-12Leadingpharm’s
-
202020-11A model of collaboration and innovation-analysis and testing center of Beijing leadingpharm medicine technology development Co., Ltd.
-
192020-11Good news: Beijing Leadingpharm Medicine Technology Development Co.,Ltd. was recognized as a pilot unit of intellectual property rights in Beijing
Warmly congratulate Beijing Leadingpharm Medicine Technology Development Co.,Ltd. on being selected as the pilot unit of intellectual property rights in Beijing in 2020-2022 -
102020-11The EG-017Ⅱ Phase II Program Seminar and Launching Meeting was successfully held
Recently, the EG-017 Phase II clinical trial program seminar and kick-off meeting jointly conducted by Beijing New Leading Zhengzhou Deep Blue Sea and Ningbo Xijian Pharmaceutical Technology Co., Ltd. was successfully held in the form of offline main venue (Beijing)+online video conference. -
212020-10Phase III clinical trial scheme discussion of recombinant human erythropoietin -Fc fusion protein for injection was successfully held
Recently, the Phase III clinical trial scheme discussion of recombinant human erythropoietin -Fc fusion protein for injection (hereinafter referred to as "rhEPO-Fc fusion protein") jointly conducted by Beijing New Leading Zhengzhou Deep Blue Sea and Shandong Danhong Pharmaceutical (a wholly-owned subsidiary of Buchang Pharmaceutical) was successfully held in the form of offline main venue (Beijing)+online video conference.
010-83057670
Address：
Marketing Department：
Leadingpharm
Pharm News
010-61006450
